Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF Stimulated vs Conventional Bone Marrow in Matched Sibling Donor Transplant
NCT00450450Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 2007
- Primary completion
- Jun 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and 2 more (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 2 years. Started Dec 2007; status: completed.
02
Drugs
filgrastim
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00450450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450450.